Pdt Partners, LLC Ngm Biopharmaceuticals Inc Transaction History

Pdt Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $111,808 - $207,578	-45,823 Reduced 61.33%	28,895 $74,000
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $110,353 - $160,191	-29,665 Reduced 28.42%	74,718 $304,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $239,095 - $906,599	70,116 Added 204.62%	104,383 $524,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $431,421 - $605,497	34,267 New	34,267 $448,000
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $403,933 - $668,132	-38,179 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $267,458 - $360,226	-19,367 Reduced 33.65%	38,179 $582,000
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $56,958 - $72,666	3,300 Added 6.08%	57,546 $1.02 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $363,626 - $472,624	18,046 Added 49.85%	54,246 $1.14 Million
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $545,172 - $1.09 Million	36,200 New	36,200 $714,000
Q2 2020 Aug 14, 2020	SELL	$11.97 - $23.47 $157,405 - $308,630	-13,150 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$10.0 - $19.51 $131,500 - $256,556	13,150 New	13,150 $162,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.